Charles River Laboratories International, Inc. (NYSE:CRL) Receives $220.75 Consensus Target Price from Brokerages

Shares of Charles River Laboratories International, Inc. (NYSE:CRL) have received an average rating of “Moderate Buy” from the sixteen research firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and twelve have given a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $220.75.

A number of equities research analysts have recently weighed in on the company. CLSA upgraded Charles River Laboratories International from a “hold” rating to an “outperform” rating and lifted their price objective for the stock from $167.00 to $219.00 in a research report on Friday, May 29th. Citigroup restated a “buy” rating on shares of Charles River Laboratories International in a report on Wednesday, July 8th. Royal Bank Of Canada initiated coverage on Charles River Laboratories International in a research note on Tuesday, April 14th. They issued an “outperform” rating and a $215.00 price target for the company. Sanford C. Bernstein set a $250.00 price target on shares of Charles River Laboratories International in a report on Wednesday, July 1st. Finally, Morgan Stanley boosted their price objective on shares of Charles River Laboratories International from $220.00 to $260.00 and gave the company an “overweight” rating in a research report on Thursday, July 9th.

Charles River Laboratories International Stock Performance

Shares of NYSE:CRL opened at $224.19 on Friday. The company has a current ratio of 1.36, a quick ratio of 1.03 and a debt-to-equity ratio of 0.90. The company has a 50-day moving average price of $192.74 and a 200-day moving average price of $186.65. The company has a market cap of $10.80 billion, a price-to-earnings ratio of -59.63, a price-to-earnings-growth ratio of 2.50 and a beta of 1.40. Charles River Laboratories International has a 12 month low of $144.26 and a 12 month high of $237.86.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.96 by $0.10. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.The company had revenue of $995.83 million for the quarter, compared to analysts’ expectations of $977.46 million. During the same period last year, the firm earned $2.34 earnings per share. Charles River Laboratories International’s quarterly revenue was up 1.2% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. As a group, equities analysts anticipate that Charles River Laboratories International will post 11.05 EPS for the current year.

Insider Buying and Selling at Charles River Laboratories International

In other news, Director James C. Foster sold 75,000 shares of Charles River Laboratories International stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $225.00, for a total transaction of $16,875,000.00. Following the sale, the director owned 31,596 shares of the company’s stock, valued at approximately $7,109,100. The trade was a 70.36% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 1.30% of the company’s stock.

Hedge Funds Weigh In On Charles River Laboratories International

Institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its holdings in Charles River Laboratories International by 0.8% in the fourth quarter. Vanguard Group Inc. now owns 5,887,175 shares of the medical research company’s stock worth $1,174,374,000 after buying an additional 47,432 shares during the period. Invesco Ltd. grew its holdings in shares of Charles River Laboratories International by 115.8% during the 4th quarter. Invesco Ltd. now owns 2,696,150 shares of the medical research company’s stock worth $537,828,000 after acquiring an additional 1,446,972 shares during the period. State Street Corp grew its holdings in shares of Charles River Laboratories International by 2.2% during the 4th quarter. State Street Corp now owns 1,871,688 shares of the medical research company’s stock worth $373,364,000 after acquiring an additional 40,535 shares during the period. Dimensional Fund Advisors LP raised its position in shares of Charles River Laboratories International by 14.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,652,484 shares of the medical research company’s stock worth $285,001,000 after acquiring an additional 210,260 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Charles River Laboratories International by 0.8% in the 4th quarter. Geode Capital Management LLC now owns 1,276,502 shares of the medical research company’s stock worth $254,186,000 after acquiring an additional 9,756 shares in the last quarter. 98.91% of the stock is owned by institutional investors.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.